{"id":756041,"date":"2023-05-08T16:03:16","date_gmt":"2023-05-08T20:03:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/"},"modified":"2023-05-08T16:03:16","modified_gmt":"2023-05-08T20:03:16","slug":"fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/","title":{"rendered":"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancers<\/em>\n        <\/li>\n<li>\n          <em>Collaboration expands FibroGen\u2019s clinical pipeline with potential first-in-class product candidate <\/em>\n        <\/li>\n<\/ul>\n<p>SAN FRANCISCO and LA JOLLA, Calif., May  08, 2023  (GLOBE NEWSWIRE) &#8212; FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on CD46. FOR46 is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and is being explored for use in other CD46 expressing cancers. As part of the clinical development strategy, FibroGen will continue Fortis Therapeutics\u2019 work to develop a PET-based biomarker utilizing a radiolabeled version of the targeting antibody (PET46) for patient selection.<\/p>\n<p>\u201cThe agreement with Fortis Therapeutics bolsters FibroGen\u2019s clinical pipeline in a capital-efficient manner, providing a product candidate with the potential to address a significant unmet medical need in oncology,\u201d said Enrique Conterno, Chief Executive Officer, FibroGen. \u201cFOR46 is a natural fit with our R&amp;D capabilities and expertise. The flexibility of the agreement gives us the opportunity to clinically develop FOR46, and ultimately acquire it as a Phase 3-ready asset, potentially delivering a therapy that may transform the treatment of patients with mCRPC and other CD46 expressing cancers.\u201d<\/p>\n<p>\u201cWe are pleased to partner with the team at FibroGen, who are experienced in advancing novel drug candidates in the clinic for life-threatening diseases,\u201d said Jay Lichter, Ph.D., President and CEO of Fortis and Managing Partner of Avalon Bioventures. \u201cWe believe that FOR46 is a novel and unique antibody drug conjugate therapy that could help patients with prostate cancer and other cancers, where currently approved treatments have failed.\u201d<\/p>\n<p>Under the terms of the agreement, there is no upfront consideration. FibroGen will conduct and fund future research, development, and manufacturing of FOR46 and PET46. During the four-year evaluation period, FibroGen has the option to acquire Fortis Therapeutics for $80 million. In addition, Fortis is eligible to receive up to a total of $200 million based on various regulatory approvals.<\/p>\n<p>\n        <strong>About FOR46<\/strong>\n      <\/p>\n<p>FOR46 is an antibody drug conjugate that binds a specific conformational epitope of CD46 that is highly expressed in various cancer types, including multiple myeloma and prostate and colorectal tumors, with limited reactivity against normal tissues. FOR46 is a fully human antibody conjugated to MMAE, a potent cytotoxic payload utilized in a variety of approved ADCs. Early clinical data show FOR46 to be generally well tolerated with demonstrated monotherapy activity in multiple myeloma and mCRPC.<\/p>\n<p>\n        <strong>About FibroGen <\/strong><br \/>\n        <br \/>FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer, and Duchenne muscular dystrophy (DMD). Roxadustat (\u7231\u745e\u5353<sup>\u00ae<\/sup>, EVRENZO\u2122) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in clinical development for anemia of chronic kidney disease (CKD) and anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology space. For more information, please visit www.fibrogen.com.<\/p>\n<p>\n        <strong>About Fortis Therapeutics<\/strong>\n      <\/p>\n<p>Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. Fortis is located in Avalon Bioventures\u2019s Community of Innovation, in San Diego. FOR46 is Fortis\u2019 sole pharmaceutical asset. For more information, please visit www.fortistx.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This release contains forward-looking statements regarding FibroGen\u2019s strategy, future plans and prospects, and the timing of potential events, including statements regarding the development and commercialization of the company\u2019s product candidates, the potential safety and efficacy profile of its product candidates, and timelines for our clinical programs. These forward-looking statements include, but are not limited to, statements about FibroGen\u2019s plans and objectives and typically are identified by use of terms such as \u201cmay,\u201d \u201cwill\u201d, \u201cshould,\u201d \u201con track,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue\u201d and similar words, although some forward-looking statements are expressed differently. FibroGen\u2019s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission (SEC) on February 27, 2023, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>\n        <strong>FibroGen, Inc.<\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Michael Tung, M.D.<br \/>Corporate Strategy \/ Investor Relations<br \/>415.978.1434<br \/>mtung@fibrogen.com<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Meichiel Jennifer Keenan<br \/>Investor Relations\/Corporate Communications<br \/>mkeenan@fibrogen.com<\/p>\n<p>\n        <strong>Fortis Therapeutics<\/strong><br \/>\n        <br \/>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Jessica Yingling<br \/>858.344.8091<br \/>jessica@litldog.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDBhMGIxOGYtMzA2NC00MWFkLWExM2QtOGI3MjEwYTNhMWY1LTEwMTk1MzY=\/tiny\/FibroGen-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancers Collaboration expands FibroGen\u2019s clinical pipeline with potential first-in-class product candidate SAN FRANCISCO and LA JOLLA, Calif., May 08, 2023 (GLOBE NEWSWIRE) &#8212; FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on CD46. FOR46 is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and is being explored for use in other CD46 expressing cancers. As part of the clinical development strategy, FibroGen will continue Fortis Therapeutics\u2019 work to develop a PET-based biomarker utilizing a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-756041","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancers Collaboration expands FibroGen\u2019s clinical pipeline with potential first-in-class product candidate SAN FRANCISCO and LA JOLLA, Calif., May 08, 2023 (GLOBE NEWSWIRE) &#8212; FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on CD46. FOR46 is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and is being explored for use in other CD46 expressing cancers. As part of the clinical development strategy, FibroGen will continue Fortis Therapeutics\u2019 work to develop a PET-based biomarker utilizing a &hellip; Continue reading &quot;FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-08T20:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics\",\"datePublished\":\"2023-05-08T20:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/\"},\"wordCount\":908,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/\",\"name\":\"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=\",\"datePublished\":\"2023-05-08T20:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics - Market Newsdesk","og_description":"FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancers Collaboration expands FibroGen\u2019s clinical pipeline with potential first-in-class product candidate SAN FRANCISCO and LA JOLLA, Calif., May 08, 2023 (GLOBE NEWSWIRE) &#8212; FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on CD46. FOR46 is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and is being explored for use in other CD46 expressing cancers. As part of the clinical development strategy, FibroGen will continue Fortis Therapeutics\u2019 work to develop a PET-based biomarker utilizing a &hellip; Continue reading \"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-08T20:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics","datePublished":"2023-05-08T20:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/"},"wordCount":908,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/","name":"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=","datePublished":"2023-05-08T20:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM1NCM1NTgxNjc1IzIwMDc5NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-enters-into-exclusive-license-for-for46-with-fortis-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=756041"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756041\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=756041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=756041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=756041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}